Terms of Use and Disclaimers
Helix BioPharma Corp. (“Helix” or the “Corporation”) maintains this website for personal informational purposes only. By accessing and browsing the Site, you accept, without limitation or qualification, these Terms of Use and Disclaimers, which are subject to change without notice to you. If you do not agree with any of the terms or conditions set forth herein, please do not use this website.

Product Information – No Medical Advice
Helix distributes pharmaceutical and medical products in Canada to assist with the treatment and/or prevention of disease. The Corporation’s products are intended only for use in countries in which they have received regulatory approval, under the direction of qualified health care professionals approved by government agencies in such countries.
Material on this website regarding the Corporation’s products is provided for information purposes only. Inclusion of products and information on this site does not imply any official medical advice, recommendation or warranty. Information provided is not a substitute for the advice of an appropriate health professional. This website can be accessed from countries around the world and may contain references to the Corporation’s products and programs that have not been granted regulatory approval in your country. Please consult your health professional for detailed information regarding the Corporation’s products and their suitability for you, as well as for regulatory approval status of such products in your country.

No Solicitation or Investment Advice
This website and the information contained herein does not constitute an offer or a solicitation of an offer for the purchase or sale of any securities. The Corporation’s web site is provided as a service only and does not contain the official versions of the Corporation’s securities law disclosure documents. The site is not intended to provide specific investment advice and investors and potential investors are advised to seek professional advice and/or refer to the Corporation’s official documents filed with the Canadian securities regulatory authorities at www.sedar.com.

Trademarks and Trade names
The Corporation owns or licenses a number of trademarks and trade names in connection with its products and services. “Helix BioPharma”, “Topical Interferon Alpha-2b”, “Klean-Prep”, “Imunovir”, “Normacol”, “Orthovisc”, “Monovisc” and “L-DOS47” are among the trade-marks and/or trade-names owned or licensed by Helix. Trade-marks and trade names are protected by Canadian and other applicable laws. All rights reserved. The display of trade-marks and trade names on this website shall not in any way be construed as an implied license to use such trademarks and trade names.

This website, and the content contained on this website, are either the property of, or used with permission of their owners by, Helix. Subject to the limited license to use this website and its contents as described herein, no person may copy, redistribute, reproduce or republish in any form, or link to this website or its contents in any manner whatsoever, unless that person has obtained the prior written consent of Helix. Any unauthorized use of this website or its content may violate intellectual property laws or other laws.
Subject to the above, Helix hereby grants you a limited license to view, print, download and otherwise use the content on this website, provided that:
● you use it for personal, non-commercial purposes only;
● you do not modify any such content;
● your copy of this content or any portion thereof retains all copyright and proprietary notices, including this limited license; and
● you do not incorporate your copy (or any part thereof) into other works without the written permission of Helix.

Limited License and Use
Except as expressly provided herein, Helix does not grant any express or implied right to you or to any person under any patents, trademarks, copyrights, trade secrets or other intellectual property.

Disclaimer of Liability
While the Corporation uses reasonable efforts to provide accurate and current information on this website, the Corporation makes no warranties or representations as to its accuracy or completeness. The Corporation assumes no responsibility or liability for any errors or omissions in the content of this website. Without limiting the generality of the foregoing, the documents and information on, and/or linked to, this website speak only as of the respective dates on which they are first made. The contents of such documents and information can become out-of-date. The Corporation makes no commitment, and disclaims any duty, to update any of those documents or information.The Corporation shall not be liable for any damages or injury resulting from your access to, or inability to access, this Site, or from your reliance on any information provided at this Site. Without limiting the foregoing, everything on the Site is provided to you “AS IS” WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT.

Helix does not review or control the contents of any linked site. These links do not constitute an endorsement by Helix of any other websites and Helix is not responsible for the information contained on such websites. Your linking to any other off-site pages or other sites is at your own risk.

Forward-Looking Statements
This website contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”). Forward-looking statements are statements that are not historical facts, and reflect the Corporation’s current expectations regarding future events. Forward-looking statements include, but are not limited to: the Corporation’s plans, objectives and expectations with respect to the development of Topical Interferon Alpha-2b and L-DOS47, including without limitation, manufacturing scale-up, future clinical trials and IND and CTA filings, indications and therapeutic and market opportunities for the two drug candidates, the nature, design and timing of future clinical trials and commercialization plans; and other information in future periods. Forward-looking statements can further be identified by the use of forward-looking terminology such as “expects”, “plans”, “designed to”, “potential”, “is developing”, “believe”, “intended”, “continues”, “opportunities”, “anticipated”, “ongoing”, “pursue”, “to seek”, “objective”, “estimate”, “future”, or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could”, “would”, or “should” occur or be achieved.
Forward-looking statements are statements about the future and are inherently uncertain, and are necessarily based upon a number of estimates and assumptions that are also uncertain. Such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material estimates or assumptions are applied in making forward-looking statements. These include, but are not limited to, the safety and efficacy of L-DOS47 and Topical Interferon Alpha-2b; the timely and successful completion of all planned activities and filings, including cGMP manufacturing and upscaling, clinical studies and clinical trials, and IND and CTA filings; the timely provision of services and supplies by third parties; future market conditions; and the receipt of required regulatory approvals, strategic partner support and necessary financing.
Forward-looking statements are subject to risks and uncertainties that may cause actual events or results to differ materially from such statements. These risks and uncertainties include, but are not limited to: Helix’s need for further financing, which may not be available; the delay or denial of any necessary regulatory approvals; that future events may not commence or be completed as planned or within expected timelines; uncertainty whether the Corporation’s drug candidates will be successfully developed or marketed; intellectual property risks, including the Corporation’s ability to protect its intellectual property, its potential violation of a third-party’s intellectual property, and its dependence on third party proprietary technology; research and development risks, including negative clinical trial results and manufacturing (including upscaling) risks; the risk that the Corporation’s supplier of interferon alpha-2b for the Corporation’s Topical Interferon Alpha-2b drug candidate may not continue to provide the Corporation with interferon alpha-2b or exercise its commercialization option; uncertainty of supply of other raw materials, including cGMP grade materials; the Corporation’s dependence on performance by third-party suppliers and service providers; product liability and insurance risks; rapid technological change and competition; the need to attract and retain skilled personnel; changes in business strategy or development plans; exchange rate fluctuations; unanticipated expenses or reductions in revenue, or both; the dependence of the Corporation’s distribution business on a few customers and a few suppliers; the Corporation’s ability to complete strategic transactions; uncertainty surrounding the commercial success of the drug candidates, if marketed; and other events beyond the control of the Corporation. Readers should consult the Corporation’s ongoing quarterly filings and annual reports for additional information on these and other risks and uncertainties affecting the Corporation’s business. The reader is cautioned not to rely on forward-looking statements.
Forward-looking statements are based on the beliefs, assumptions, opinions and expectations of Helix’s management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.